These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 16377036)

  • 1. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
    Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Construction and expression of Plasmodium berghei chimeric protein in Pichia pastoris and its immunogenicity in mice].
    Cao Y; Zhang DM; Pan WQ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2008 Oct; 26(5):327-31. PubMed ID: 19157293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S; Mukherjee P; Yazdani SS; Jain SK; Mohmmed A; Chauhan VS
    Infect Immun; 2010 Feb; 78(2):872-83. PubMed ID: 19933832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity.
    Singh S; Miura K; Zhou H; Muratova O; Keegan B; Miles A; Martin LB; Saul AJ; Miller LH; Long CA
    Infect Immun; 2006 Aug; 74(8):4573-80. PubMed ID: 16861644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Pattnaik P; Shakri AR; Singh S; Goel S; Mukherjee P; Chitnis CE
    Vaccine; 2007 Jan; 25(5):806-13. PubMed ID: 17045706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village.
    Perraut R; Marrama L; Diouf B; Sokhna C; Tall A; Nabeth P; Trape JF; Longacre S; Mercereau-Puijalon O
    J Infect Dis; 2005 Jan; 191(2):264-71. PubMed ID: 15609237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK; Mukherjee P; Dhawan S; Pandey AK; Mazumdar S; Gaur D; Jain SK; Chauhan VS
    Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG subclass antibodies to three variants of Plasmodium falciparum merozoite surface protein-1 (PfMSP-1(19)) in an area with unstable malaria transmission in Iran.
    Mehrizi AA; Asgharpour S; Salmanian AH; Djadid ND; Zakeri S
    Acta Trop; 2011 Aug; 119(2-3):84-90. PubMed ID: 21609709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
    Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae.
    Hui GS; Gosnell WL; Case SE; Hashiro C; Nikaido C; Hashimoto A; Kaslow DC
    J Immunol; 1994 Sep; 153(6):2544-53. PubMed ID: 8077664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.
    Carvalho LJ; Oliveira SG; Theisen M; Alves FA; Andrade MC; Zanini GM; Brígido MC; Oeuvray C; Póvoa MM; Muniz JA; Druilhe P; Daniel-Ribeiro CT
    Scand J Immunol; 2004 Apr; 59(4):363-72. PubMed ID: 15049780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
    Theisen M; Soe S; Brunstedt K; Follmann F; Bredmose L; Israelsen H; Madsen SM; Druilhe P
    Vaccine; 2004 Mar; 22(9-10):1188-98. PubMed ID: 15003647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.